“P053 | LONG-TERM EFFECTIVENESS AND SAFETY OF FREMANEZUMAB FOR MIGRAINE PREVENTION: 24-MONTH OUTCOMES FROM THE ITALIAN COHORT OF THE PEARL STUDY: S. Guerzoni1, C. Aurilia2, A. Doretti3, E. Maria Piella4, R. Ornello5, P. Kokturk6, M. Cepparulo7 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology- Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico Di Modena, Italy; 2Headache and Pain Unit, IRCCS San Raffaele, Rome, Italy; 3Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; 4Neurosciences Department, University of Turin, Italy; 5Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; 6Teva Netherlands B.V., Haarlem, The Netherlands; 7Teva Italia Srl, Milan, Italy”. 2026. Confinia Cephalalgica 36 (s1). https://doi.org/10.4081/cc.2026.16009.